Orchestra Biomed Holdings, Inc. (OBIO)
NASDAQ:OBIO
Want to see OBIO full AI Analyst Report?
Top Page
Orchestra BioMed Holdings
(NASDAQ:OBIO)
Select Model
Select Model
Rating:41Neutral
Price Target:
$4.00
▼(-12.66% Downside)
Action:Reiterated
Date:05/16/26
OBIO scores low primarily due to sustained unprofitability and significant ongoing cash burn, which raise financing risk despite low leverage. Technicals are also weak with the stock trading below major moving averages and a negative MACD. Valuation provides little support because earnings are negative and no dividend yield is available.
Positive Factors
Low leverage / sizable balance sheet
A very low debt-to-equity (~0.04) and sizable assets provide durable financial flexibility for a capital-intensive biotech. This balance-sheet strength reduces near-term refinancing risk, supports continued clinical programs, and gives management optionality for partnerships or milestone-focused spend over the next several months.
Negative Factors
Heavy, persistent cash burn
Sustained negative operating and free cash flow of roughly -$54M TTM implies ongoing reliance on external financing. Over a multi-month horizon this creates execution risk: clinical programs and milestone payments depend on capital raises, which can dilute shareholders and constrain strategic optionality if markets tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / sizable balance sheet
A very low debt-to-equity (~0.04) and sizable assets provide durable financial flexibility for a capital-intensive biotech. This balance-sheet strength reduces near-term refinancing risk, supports continued clinical programs, and gives management optionality for partnerships or milestone-focused spend over the next several months.
Read all positive factors
Orchestra BioMed Holdings (OBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$243.12M
Dividend YieldN/A
Average Volume (3M)230.49K
Price to Earnings (P/E)―
Beta (1Y)1.90
Revenue Growth1033.89%
EPS Growth36.35%
CountryUS
Employees70
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.33
Shares Outstanding59,880,714
10 Day Avg. Volume307,413
30 Day Avg. Volume230,490
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)2.51
Price to Sales (P/S)4.76
P/FCF Ratio-3.22
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue6.61
Enterprise Value/Gross Profit6.66
Enterprise Value/Ebitda-3.98
Forecast
1Y Price Target
$12.83Price Target Upside180.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.64
Revenue Forecast (FY)$545.43K
Orchestra BioMed Holdings Business Overview & Revenue Model
Company Description
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Bal...
How the Company Makes Money
null...
Orchestra BioMed Holdings Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
68
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.72M | 33.48M | 2.64M | 2.76M | 3.53M | -782.00K |
| Gross Profit | 32.49M | 33.29M | 2.43M | 2.57M | 3.21M | -981.00K |
| EBITDA | -54.37M | -51.23M | -63.99M | -51.22M | -32.44M | -21.62M |
| Net Income | -54.64M | -52.70M | -61.02M | -49.12M | -33.61M | -23.01M |
Balance Sheet | ||||||
| Total Assets | 100.66M | 114.86M | 76.17M | 95.21M | 95.57M | 13.53M |
| Cash, Cash Equivalents and Short-Term Investments | 94.40M | 106.51M | 66.81M | 87.59M | 83.78M | 10.90M |
| Total Debt | 1.51M | 1.69M | 16.53M | 1.69M | 11.87M | 5.67M |
| Total Liabilities | 49.69M | 51.48M | 43.22M | 27.17M | 43.04M | 84.76M |
| Stockholders Equity | 50.97M | 63.38M | 32.96M | 68.04M | 52.53M | -71.23M |
Cash Flow | ||||||
| Free Cash Flow | -55.08M | -49.45M | -50.85M | -46.20M | -29.88M | -19.70M |
| Operating Cash Flow | -54.52M | -48.96M | -50.56M | -46.13M | -29.29M | -19.43M |
| Investing Cash Flow | -29.62M | -26.94M | 13.09M | 10.69M | -64.12M | 13.02M |
| Financing Cash Flow | 94.16M | 88.33M | 29.17M | 46.22M | 103.26M | -3.99M |
Orchestra BioMed Holdings Technical Analysis
Positive
4.58
Price Trends
4.23
Negative
4.21
Negative
3.85
Positive
Market Momentum
-0.05
Negative
49.51
Neutral
76.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OBIO, the sentiment is Positive. The current price of 4.58 is above the 20-day moving average (MA) of 3.99, above the 50-day MA of 4.23, and above the 200-day MA of 3.85, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 49.51 is Neutral, neither overbought nor oversold. The STOCH value of 76.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OBIO.
Orchestra BioMed Holdings Risk Analysis
Orchestra BioMed Holdings disclosed 81 risk factors in its most recent earnings report. Orchestra BioMed Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Orchestra BioMed Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $629.87M | ― | -31.46% | ― | ― | 67.20% | |
53 Neutral | $112.77M | -3.71 | -72.68% | ― | ― | 64.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $124.18M | -1.00 | -135.60% | ― | ― | 17.43% | |
47 Neutral | $121.70M | -2.24 | -95.51% | ― | -10.71% | 28.59% | |
41 Neutral | $243.12M | ― | -137.99% | ― | 1033.89% | 36.35% |
* Healthcare Sector Average
OBIO
Orchestra BioMed Holdings
4.06
1.24
43.97%
CRDF
Cardiff Oncology
1.78
-1.25
-41.25%
GLSI
Greenwich LifeSciences
27.65
17.67
177.05%
CLYM
Climb Bio
11.00
9.83
840.17%
CGTX
Cognition Therapeutics
1.26
1.00
384.62%
PYXS
Pyxis Oncology
1.96
0.72
58.06%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.